{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:27Z","timestamp":1792167507156,"version":"4.4.0"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) is an important risk factor for the development of heart failure (HF), both directly by impairing cardiac function and indirectly through related conditions such as hypertension, coronary heart disease, renal dysfunction, and other metabolic disorders. The prevention of T2DM-related HF is a comprehensive management process involving complex and multifactorial pathogenic mechanisms. An in-depth exploration of the pathophysiological and clinical risk factors of HF in T2DM can assist clinicians in identifying individuals at high risk of HF, enabling early intervention measures to prevent its onset. In this review, we present data on the pathophysiology and epidemiology of T2DM-mediated HF, clinical phenotypic features of cardiomyopathy, and summarize clinical risk factors predicting HF development identified in multiple studies, risk assessment tools, and clinical trial data on the efficacy of lifestyle modifications, pharmacological treatments, and bariatric surgical interventions. Finally, we discuss best practice recommendations for clinicians, highlight potential limitations and challenges, and propose possible future research directions.<\/jats:p>","DOI":"10.3389\/fendo.2025.1630686","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:18:06Z","timestamp":1757477886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinv","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","article-title":"Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial","volume":"16","author":"Natali","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: A report of the heart failure society of america, heart failure association of the european society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pcad.2023.05.002","article-title":"Biomarkers for the diagnosis of heart failure in people with diabetes: A consensus report from diabetes technology society","volume":"79","author":"Yeung","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024833","article-title":"Clinical prediction models for heart failure hospitalization in type 2 diabetes: A systematic review and meta-analysis","volume":"11","author":"Razaghizad","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-021-01378-4","article-title":"Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM\/BiomarCaRE consortium","volume":"20","author":"Vuori","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973083","article-title":"Non-invasive diagnostic imaging techniques as a window into the diabetic heart: a review of experimental and clinical data","volume":"115","author":"Korosoglou","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13475","article-title":"Assessment of subclinical diabetic cardiomyopathy by speckle-tracking imaging","volume":"51","author":"Minciuna","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4390-4","article-title":"Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease","volume":"61","author":"Jia","year":"2018","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.08.008","article-title":"Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study","volume":"170","author":"Lazo","year":"2015","journal-title":"Am Heart J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001990","article-title":"Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study","volume":"8","author":"Skali","year":"2015","journal-title":"Circ Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01514","article-title":"Diabetic cardiomyopathy: current and future therapies","volume":"9","author":"Borghetti","year":"2018","journal-title":"Beyond Glycemic Control. Front Physiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00128-6","article-title":"Predicting and preventing heart failure in type 2 diabetes","volume":"11","author":"Pandey","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(03)00625-9","article-title":"Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus","volume":"42","author":"Diamant","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.06.021","article-title":"Screening for heart disease in diabetic subjects","volume":"149","author":"Fang","year":"2005","journal-title":"Am Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.echo.2011.07.017","article-title":"Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy","volume":"24","author":"Ernande","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1032268","article-title":"Diabetic cardiomyopathy: Clinical phenotype and practice","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.612","article-title":"The association between glucose abnormalities and heart failure in the population-based Reykjavik study","volume":"28","author":"Thrainsdottir","year":"2005","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4926-x","article-title":"Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals","volume":"62","author":"Ohkuma","year":"2019","journal-title":"Diabetologia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000343","article-title":"Sex differences in the cardiovascular consequences of diabetes mellitus: A scientific statement from the american heart association","volume":"132","author":"Regensteiner","year":"2015","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/ijph.2022.1604472","article-title":"Association between cardiovascular disease risk factors and mortality in adults with diabetes: A stratified analysis by sex, race, and ethnicity","volume":"67","author":"Savage","year":"2022","journal-title":"Int J Public Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.010815","article-title":"Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage","volume":"130","author":"Selvin","year":"2014","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1164-z","article-title":"HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study","volume":"51","author":"Pazin-Filho","year":"2008","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0165","article-title":"The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study","volume":"59","author":"Matsushita","year":"2010","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jchf.2021.06.005","article-title":"Duration of diabetes and incident heart failure: the ARIC (Atherosclerosis risk in communities) study","volume":"9","author":"Echouffo-Tcheugui","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.43","article-title":"The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation","volume":"23","author":"Franjic","year":"2009","journal-title":"J Hum Hypertens"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx721","article-title":"Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction","volume":"39","author":"Taqueti","year":"2018","journal-title":"Eur Heart J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018799","article-title":"Quantifying the sex-race\/ethnicity-specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES","volume":"10","author":"Cameron","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Piche","year":"2020","journal-title":"Circ Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.089011","article-title":"Metabolic syndrome and risk for heart failure in middle-aged men","volume":"92","author":"Ingelsson","year":"2006","journal-title":"Heart"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.09.006","article-title":"Physical activity, fitness, and obesity in heart failure with preserved ejection fraction","volume":"6","author":"Pandey","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050941","article-title":"Association of baseline and longitudinal changes in body composition measures with risk of heart failure and myocardial infarction in type 2 diabetes: findings from the look AHEAD trial","volume":"142","author":"Patel","year":"2020","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2022","journal-title":"Cardiorenal Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-023-01796-6","article-title":"Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes","volume":"22","author":"Tao","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac285","article-title":"Clinical implications and guidelines for CKD in type 2 diabetes","volume":"38","author":"Zhang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2015.11.011","article-title":"Noninvasive cardiovascular risk assessment of the asymptomatic diabetic patient: the imaging council of the american college of cardiology","volume":"9","author":"Budoff","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.17-191","article-title":"Coronary artery disease and type 2 diabetes mellitus","volume":"58","author":"Naito","year":"2017","journal-title":"Int Heart J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000170","article-title":"Screening for asymptomatic coronary artery disease in patients with type 2 diabetes mellitus","volume":"60","author":"Tavares","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","article-title":"Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes","volume":"9","author":"Ho","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-7-9","article-title":"Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus","volume":"7","author":"Yang","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.05.056","article-title":"A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study","volume":"162","author":"Pfister","year":"2013","journal-title":"Int J Cardiol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008503","article-title":"Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study","volume":"5","author":"Hippisley-Cox","year":"2015","journal-title":"BMJ Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1159\/000478995","article-title":"Cardiac computed tomography angiographic findings as predictors of late heart failure in an asymptomatic diabetic cohort: an 8-year prospective follow-up study","volume":"138","author":"Halon","year":"2017","journal-title":"Cardiology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23298","article-title":"A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus","volume":"43","author":"Williams","year":"2020","journal-title":"Clin Cardiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2723","article-title":"Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2375","article-title":"Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia","volume":"24","author":"Segar","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024094","article-title":"Validation of the WATCH-DM and TRS-HF(DM) risk scores to predict the risk of incident hospitalization for heart failure among adults with type 2 diabetes: A multicohort analysis","volume":"11","author":"Segar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14015","article-title":"Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14283","article-title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF(DM)) in patients in the ACCORD trial","volume":"23","author":"Elharram","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cardfail.2022.05.013","article-title":"Longitudinal changes in cardiac troponin and risk of heart failure among black adults","volume":"29","author":"Saha","year":"2023","journal-title":"J Card Fail"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.11.027","article-title":"Stress cardiac biomarkers, cardiovascular and renal outcomes, and response to canagliflozin","volume":"79","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4727-7","article-title":"Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study","volume":"61","author":"Fraty","year":"2018","journal-title":"Diabetologia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rec.2021.07.001","article-title":"Survival analyses in cardiovascular research, part II: statistical methods in challenging situations","volume":"75","author":"Rossello","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2018.1460576","article-title":"Novel heart failure biomarkers: why do we fail to exploit their potential","volume":"55","author":"Piek","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.11.003","article-title":"High-sensitivity cardiac troponin and new-onset heart failure: A systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events","volume":"6","author":"Evans","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-668x(03)00476-7","article-title":"Clinical applications of B-type natriuretic peptide (BNP) testing","volume":"24","author":"Cowie","year":"2003","journal-title":"Eur Heart J"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the american diabetes association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12933-022-01616-3","article-title":"Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study","volume":"21","author":"Sabbatinelli","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.02.007","article-title":"The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota","volume":"20","author":"Dandamudi","year":"2014","journal-title":"J Card Fail"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-307391","article-title":"Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus","volume":"101","author":"Holland","year":"2015","journal-title":"Heart"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.06.024","article-title":"3-dimensional echocardiography: latest developments and future directions","volume":"11","author":"Lang","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-019-0876-3","article-title":"Impact of acute hyperglycemia on layer-specific left ventricular strain in asymptomatic diabetic patients: an analysis based on two-dimensional speckle tracking echocardiography","volume":"18","author":"Bogdanovic","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-020-01768-x","article-title":"Evaluation of the left atrial function by two-dimensional speckle-tracking echocardiography in diabetic patients with obesity","volume":"36","author":"Mohseni-Badalabadi","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"key":"B92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12933-016-0333-5","article-title":"Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus","volume":"15","author":"Liu","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108604","article-title":"The role of cardiac fibrosis in diabetic cardiomyopathy: from pathophysiology to clinical diagnostic tools","volume":"24","author":"Pan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.576","article-title":"Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis","volume":"305","author":"Umpierre","year":"2011","journal-title":"JAMA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21404","article-title":"Effects of clinically significant weight loss with exercise training on insulin resistance and cardiometabolic adaptations","volume":"24","author":"Swift","year":"2016","journal-title":"Obes (Silver Spring)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.165571","article-title":"Effects of exercise intervention on myocardial function in type 2 diabetes","volume":"95","author":"Hordern","year":"2009","journal-title":"Heart"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13121631","article-title":"Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function","volume":"269","author":"Jonker","year":"2013","journal-title":"Radiology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look","year":"2013","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044865","article-title":"Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the look AHEAD trial","volume":"141","author":"Pandey","year":"2020","journal-title":"Circulation"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102869","article-title":"Metabolic effects of metformin in the failing heart","volume":"19","author":"Dziubak","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09942-y","article-title":"Metformin and heart failure-related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials","volume":"26","author":"Dludla","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056756","article-title":"Effects of long-term metformin and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study","volume":"145","author":"Goldberg","year":"2022","journal-title":"Circulation"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13448","article-title":"Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure","volume":"20","author":"Weir","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2018.0127","article-title":"The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure","volume":"76","author":"Retwinski","year":"2018","journal-title":"Kardiol Pol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0167","article-title":"Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies","volume":"31","author":"Rao","year":"2008","journal-title":"Diabetes Care"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4312","article-title":"Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes","volume":"311","author":"Roumie","year":"2014","journal-title":"JAMA"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch Med Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.10.026","article-title":"Treatment of diabetes in people with heart failure","author":"Connelly","year":"2018","journal-title":"Can J Diabetes"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3477","article-title":"Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care","volume":"354","author":"Hippisley-Cox","year":"2016","journal-title":"BMJ"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-019-0960-8","article-title":"Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14","volume":"18","author":"Pratley","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Fernandez\u2212Balsells","year":"2017","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165807","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B126","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFbeta1\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114674","article-title":"Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts","volume":"192","author":"Lee","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00391.2022","article-title":"Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca(2+) handling in ventricular cardiomyocytes","volume":"324","author":"Kadosaka","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat Metab"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B135","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa534","article-title":"Patient-centered management of type 2 diabetes mellitus based on specific clinical scenarios: systematic review, meta-analysis and trial sequential analysis","volume":"105","author":"Pinto","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2018.03.013","article-title":"Hypertension in patients with type 2 diabetes mellitus: Targets and management","volume":"112","author":"Pavlou","year":"2018","journal-title":"Maturitas"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215362","article-title":"Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis","volume":"14","author":"Wang","year":"2019","journal-title":"PloS One"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: A position statement by the american diabetes association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw155","article-title":"Finerenone in heart failure: walking a fine line","volume":"37","author":"Naegele","year":"2016","journal-title":"Eur Heart J"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sjostrom","year":"2007","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066603","article-title":"Long-term mortality after gastric bypass surgery","volume":"357","author":"Adams","year":"2007","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz295","article-title":"Surgical obesity treatment and the risk of heart failure","volume":"40","author":"Jamaly","year":"2019","journal-title":"Eur Heart J"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: A nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.01.047","article-title":"Long-term cardiovascular outcomes after bariatric surgery in the medicare population","volume":"79","author":"Mentias","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpt215","article-title":"Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis","volume":"27","author":"Cuspidi","year":"2014","journal-title":"Am J Hypertens"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu116","article-title":"Ventricular remodelling post-bariatric surgery: is the type of surgery relevant? A prospective study with 3D speckle tracking","volume":"15","author":"Kaier","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1748-x","article-title":"Weight loss with sleeve gastrectomy in obese type 2 diabetes mellitus: impact on cardiac function","volume":"26","author":"Leung","year":"2016","journal-title":"Obes Surg"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2301-2","article-title":"Early reverse cardiac remodeling effect of laparoscopic sleeve gastrectomy","volume":"27","author":"Tuluce","year":"2017","journal-title":"Obes Surg"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2330-x","article-title":"Beneficial effects of bariatric surgery on cardiac structure and function in obesity","volume":"27","author":"Shin","year":"2017","journal-title":"Obes Surg"},{"key":"B168","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5603\/CJ.a2017.0059","article-title":"Improvement of left ventricular diastolic function and left heart morphology in young women with morbid obesity six months after bariatric surgery","volume":"25","author":"Kurnicka","year":"2018","journal-title":"Cardiol J"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.019","article-title":"Hemodynamic effects of weight loss in obesity: A systematic review and meta-analysis","volume":"7","author":"Reddy","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09669-7","article-title":"Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease","volume":"22","author":"Bakbak","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (Gastric bypass to treat obese patients with steady hypertension)","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00757-5","article-title":"Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia","volume":"19","author":"Sandoval","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1086978","article-title":"Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes","volume":"10","author":"Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-023-02001-4","article-title":"High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction","volume":"22","author":"Zhou","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-025-02595-x","article-title":"Association between insulin resistance indices and outcomes in patients with heart failure with preserved ejection fraction","volume":"24","author":"Ni","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2016.1217775","article-title":"Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential","volume":"13","author":"Tunon","year":"2016","journal-title":"Expert Rev Proteomics"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094937","article-title":"Traditional and emerging biomarkers in asymptomatic left ventricular dysfunction-promising non-coding RNAs and exosomes as biomarkers in early phases of cardiac damage","volume":"22","author":"Janjusevic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.926378","article-title":"Detection of myocardial fibrosis: Where we stand","volume":"9","author":"Zhu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144962","article-title":"The mitochondria: A target of polyphenols in the treatment of diabetic cardiomyopathy","volume":"21","author":"Bhagani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.88476","article-title":"Ferroptosis: A new mechanism in diabetic cardiomyopathy","volume":"21","author":"Song","year":"2024","journal-title":"Int J Med Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1630686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:18:07Z","timestamp":1757477887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1630686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":180,"alternative-id":["10.3389\/fendo.2025.1630686"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1630686","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1630686"}}